Morgan Stanley’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-576,774
| Closed | -$10.7M | – | 8009 |
|
|
2023
Q3 | $10.7M | Buy |
576,774
+434,872
| +306% | +$4.92M | ﹤0.01% | 3072 |
|
|
2023
Q2 | $1.57M | Sell |
141,902
-225,879
| -61% | -$3.15M | ﹤0.01% | 4575 |
|
|
2023
Q1 | $4.94M | Sell |
367,781
-404,599
| -52% | -$7M | ﹤0.01% | 3801 |
|
|
2022
Q4 | $9.55M | Sell |
772,380
-125,593
| -14% | -$1.78M | ﹤0.01% | 3139 |
|
|
2022
Q3 | $12.5M | Sell |
897,973
-163,196
| -15% | -$2.63M | ﹤0.01% | 2721 |
|
|
2022
Q2 | $14.7M | Buy |
1,061,169
+494,677
| +87% | +$7.92M | ﹤0.01% | 2628 |
|
|
2022
Q1 | $9.22M | Buy |
566,492
+372,527
| +192% | +$5.84M | ﹤0.01% | 2992 |
|
|
2021
Q4 | $3.16M | Buy |
193,965
+21,289
| +12% | +$359K | ﹤0.01% | 4196 |
|
|
2021
Q3 | $2.56M | Sell |
172,676
-402,135
| -70% | -$6.43M | ﹤0.01% | 4372 |
|
|
2021
Q2 | $11.5M | Buy |
574,811
+414,090
| +258% | +$8.21M | ﹤0.01% | 2828 |
|
|
2021
Q1 | $3.71M | Sell |
160,721
-143,776
| -47% | -$4.01M | ﹤0.01% | 3723 |
|
|
2020
Q4 | $7.52M | Buy |
304,497
+247,065
| +430% | +$8.19M | ﹤0.01% | 2822 |
|
|
2020
Q3 | $2.38M | Buy |
57,432
+1,563
| +3% | +$71.8K | ﹤0.01% | 3501 |
|
|
2020
Q2 | $2.68M | Sell |
55,869
-7,702
| -12% | -$595K | ﹤0.01% | 3314 |
|
|
2020
Q1 | $4M | Sell |
63,571
-8,585
| -12% | -$772K | ﹤0.01% | 2665 |
|
|
2019
Q4 | $8.94M | Buy |
72,156
+26,339
| +57% | +$2.36M | ﹤0.01% | 2545 |
|
|
2019
Q3 | $3.04M | Buy |
45,817
+2,257
| +5% | +$152K | ﹤0.01% | 3405 |
|
|
2019
Q2 | $3.47M | Buy |
43,560
+1,740
| +4% | +$156K | ﹤0.01% | 3294 |
|
|
2019
Q1 | $4.68M | Sell |
41,820
-148,677
| -78% | -$16.2M | ﹤0.01% | 2780 |
|
|
2018
Q4 | $19.2M | Buy |
190,497
+15,592
| +9% | +$1.62M | 0.01% | 1495 |
|
|
2018
Q3 | $22.1M | Buy |
174,905
+92,909
| +113% | +$9.83M | 0.01% | 1592 |
|
|
2018
Q2 | $6.88M | Buy |
81,996
+55,187
| +206% | +$4.04M | ﹤0.01% | 2787 |
|
|
2018
Q1 | $1.65M | Sell |
26,809
-397,210
| -94% | -$23.9M | ﹤0.01% | 4163 |
|
|
2017
Q4 | $24.8M | Buy |
424,019
+207,283
| +96% | +$13.1M | 0.01% | 1481 |
|
|
2017
Q3 | $12.6M | Buy |
216,736
+203,666
| +1,558% | +$21.9M | ﹤0.01% | 2049 |
|
|
2017
Q2 | $1.58M | Buy |
13,070
+2,623
| +25% | +$304K | ﹤0.01% | 4001 |
|
|
2017
Q1 | $1.18M | Sell |
10,447
-104
| -1% | -$12.1K | ﹤0.01% | 4254 |
|
|
2016
Q4 | $1.15M | Sell |
10,551
-8,862
| -46% | -$1.06M | ﹤0.01% | 4361 |
|
|
2016
Q3 | $3.2M | Buy |
19,413
+9,995
| +106% | +$1.58M | ﹤0.01% | 3106 |
|
|
2016
Q2 | $1.34M | Buy |
9,418
+5,346
| +131% | +$779K | ﹤0.01% | 3738 |
|
|
2016
Q1 | $523K | Sell |
4,072
-16,851
| -81% | -$1.99M | ﹤0.01% | 4408 |
|
|
2015
Q4 | $3.12M | Sell |
20,923
-6,970
| -25% | -$1.18M | ﹤0.01% | 3104 |
|
|
2015
Q3 | $4.63M | Sell |
27,893
-72,600
| -72% | -$16M | ﹤0.01% | 2723 |
|
|
2015
Q2 | $24.3M | Sell |
100,493
-3,354
| -3% | -$893K | 0.01% | 1332 |
|
|
2015
Q1 | $29.3M | Sell |
103,847
-5,569
| -5% | -$1.21M | 0.01% | 1169 |
|
|
2014
Q4 | $17.1M | Sell |
109,416
-15,282
| -12% | -$2.82M | 0.01% | 1584 |
|
|
2014
Q3 | $29.5M | Buy |
124,698
+39,854
| +47% | +$10.2M | 0.01% | 1144 |
|
|
2014
Q2 | $20.1M | Buy |
84,844
+2,395
| +3% | +$631K | 0.01% | 1432 |
|
|
2014
Q1 | $27.2M | Buy |
82,449
+81,351
| +7,409% | +$27.5M | 0.01% | 1134 |
|
|
2013
Q4 | $75K | Buy |
+1,098
| New | +$63.5K | ﹤0.01% | 5458 |
|
Morgan Stanley's ICPT Position: Q4 2023 in Review
Morgan Stanley sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 576,774 shares — an estimated $10.7M sold.
Morgan Stanley first reported a position in ICPT in Q4 2013 and held it in 40 quarters. The position peaked at $29.5M in Q3 2014. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Morgan Stanley reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Morgan Stanley sold 576,774 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $10.7M.
- Morgan Stanley first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 40 quarters.
- Morgan Stanley's Intercept Pharmaceuticals, Inc. position peaked at $29.5M in Q3 2014.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.